Expression of p53 and Ki-67 as prognostic factors for survival of men with colorectal cancer

Anticancer Research

Volumn 32, Issue 9, 2012, Pages 3965-3967

  Lumachi, Franco ^a   Orlando, Rocco ^a   Marino, Filippo ^a   Chiara, Giordano B ^b   Basso, Stefano M M ^b  

^a UNIVERSITY OF PADOVA   (Italy)

^b S MARIA DEGLI ANGELI HOSPITAL   (Italy)

Author keywords

CEA; Colorectal cancer; Ki 67; MIB 1; p53; Prognostic factors; Survival; Tissue proliferation marker

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; KI 67 ANTIGEN; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; HUMAN; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL TIME;

ADENOCARCINOMA; AGED; CARCINOEMBRYONIC ANTIGEN; COLORECTAL NEOPLASMS; HUMANS; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84866981242     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Horton JK and Tepper JE: Staging of colorectal cancer: Past, present, and future. Clin Colorectal Cancer 4: 302-312, 2005.
2. Kikuchi M, MikamilT, Sato T, Tokuyamal W, Arakil K, Watanabe M, Saigenji K and Okayasul I: High Ki-67, Bax, and thymidylate synthase expression well correlates with response to chemoradiation therapy in locally advanced rectal cancers: Proposal of a logistic model for prediction. Br J Cancer 101: 116-123, 2009.
3. Hanby AM: Aspects of molecular phenotype and its correlations with breast cancer behaviour and taxonomy. Br J Cancer 92: 613-617, 2005.
4. Petit T, Wilt M, Velten M, Millon R, Rodier JF, Borel C, Mors R, Haegelé P, Eber M and Ghnassia JP: Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Eur J Cancer 40: 205-211, 2004.
5. Han JS, Cao D, Molberg KH, Sarode VR, Rao R, Sutton LM and Peng Y: Hormone receptor status rather than HER2 status is significantly associated with increased Ki-67 and p53 expression in triple-negative breast carcinomas, and high expression of Ki-67 but not p53 is significantly associated with axillary nodal metastasis in triple-negative and high-grade non-triple-negative breast carcinomas. Am J Clin Pathol 135: 230-237, 2011.
6. Lan YT, Chang SC, Li AF, Lin TC, Chen WS, Jiang JK, Yang SH, Wang HS and Lin JK: p53 protein accumulation as a prognostic marker in sporadic colorectal cancer. Int J Colorectal Dis 22: 499-506, 2007.
7. Fluge Ø, Gravdal K, Carlsen E, Vonen B, Kjellevold K, Refsum S, Lilleng R, Eide TJ, Halvorsen TB, Tveit KM, Otte AP, Akslen LA and Dahl O; Norwegian Gastrointestinal Cancer Group: Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis. Br J Cancer 101: 1282-1289, 2009.
8. Al-Rawi NH, Omer H and Al Kawas S: Immunohistochemical analysis of p53 and BCL-2 in benign and malignant salivary glands tumors. J Oral Pathol Med 39 : 48-55, 2010.
9. Hashizume K, Hatanaka Y, Kamihara Y and Tani Y: Automated immunohistochemical staining of formalin-fixed and paraffin-embedded tissues using a catalyzed signal amplification method. Appl Immunohistochem Mol Morphol 9: 54-60, 2001.
10. Lumachi F, Basso SM, Brandes AA, Pagano D and Ermani M: Relationship between tumor markers CEA and CA 15-3, TNM staging, estrogen receptor rate and MIB-1 index in patients with pT1-2 breast cancer. Anticancer Res 24: 3221-3224, 2004.
11. Lumachi F, Norberto L, Zanella S, Marino F, Basso SMM, Basso U, Brunello A and Fassina A: Axillary node sampling in conjunction with sentinel node biopsy in patients with breast cancer. A prospective preliminary study. Anticancer Res 31: 693-698, 2011.
12. Nicolini A, Carpi A and Tarro G: Biomolecular markers of breast cancer. Front Biosci 11: 1818-1843, 2006.
13. Baak JP, Gudlaugsson E, Skaland I, Guo LH, Klos J, Lende TH, Soiland H, Janssen EA and Zur Hausen A: Proliferation is the strongest prognosticator in node-negative breast cancer: Significance, error sources, alternatives and comparison with molecular prognostic markers. Breast Cancer Res Treat 115: 241-254, 2009.
14. de Sousa-Júnior EC, Alencar AP and da Silva BB: Ki-67 and BCL-2 antigen expression in adenomatous colorectal polyps from women with breast cancer. Ann Surg Oncol 17: 2378-2383, 2010.
15. Jones RL, Salter J, A'Hern R, Nerurkar A, Parton M, Reis-Filho JS, Smith IE and Dowsett M: The prognostic significance of Ki-67 before and after neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 116: 53-68, 2009.
16. Ishida H, Miwa H, Tatsuta M, Masutani S, Imamura H, Shimizu J, Ezumi K, Kato H, Kawasaki T, Furukawa H and Kawakami H: Ki-67 and CEA expression as prognostic markers in Dukes' C colorectal cancer. Cancer Lett 15: 109-115, 2004.
17. Kimura T, Tanaka S, Haruma K, Sumii K, Kajiyma G, Shimamoto F and Kohno N: Clinical significance of MUC1 and E-cadherin expression, cellular proliferation, and angiogenesis at the deepest invasive portion of colorectal cancer. Int J Oncol 16: 55-64, 2000.
18. Allegra CJ, Paik S, Colangelo LH, Parr AL, Kirsch I, Kim G, Klein P, Johnston PG, Wolmark N and Wieand HS: Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: A National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study. J Clin Oncol 21: 241-250, 2003.
19. Lacroix M, Toillon RA and Leclercq G: p53 and breast cancer, an update. Endocr Relat Cancer 13: 293-325, 2006.
20. Theodoropoulos GE, Karafoka E, Papailiou JG, Stamopoulos P, Zambirinis CP, Bramis K, Panoussopoulos SG, Leandros E and Bramis J: P53 and EGFR expression in colorectal cancer: A reappraisal of 'old' tissue markers in patients with long follow-up. Anticancer Res 29: 785-791, 2009.
21. Huh JW, Lee JH and Kim HR: Expression of p16, p53, and Ki-67 in colorectal adenocarcinoma: A study of 356 surgically resected cases. Hepatogastroenterology 57: 734-740, 2010.
22. Cui T, Chen Y, Yang L, Knösel T, Zöller K, Huber O and Petersen I: DSC3 expression is regulated by p53, and methylation of DSC3 DNA is a prognostic marker in human colorectal cancer. Br J Cancer 104: 1013-1019, 2011.
23. Popat S, Chen Z, Zhao D, Pan H, Hearle N, Chandler I, Shao Y, Aherne W and Houlston R: A prospective, blinded analysis of thymidylate synthase and p53 expression as prognostic markers in the adjuvant treatment of colorectal cancer. Ann Oncol 17: 1810-1817, 2006.
24. Torsello A, Garufi C, Cosimelli M, Diodoro MG, Zeuli M, Vanni B, Campanella C, D'Angelo C, Sperduti I, Perrone Donnorso R, Cognetti F, Terzoli E and Mottolese M: p53 and BCL-2 in colorectal cancer arising in patients under 40 years of age: Distribution and prognostic relevance. Eur J Cancer 44: 1217-1222, 2008.
25. Pancione M, Forte N, Fucci A, Sabatino L, Febbraro A, Di Blasi A, Daniele B, Parente D and Colantuoni V: Prognostic role of beta-catenin and p53 expression in the metastatic progression of sporadic colorectal cancer. Hum Pathol 41: 867-876, 2010.
26. Suppiah A, Alabi A, Madden L, Hartley JE, Monson JR and Greenman J: Anti-p53 autoantibody in colorectal cancer: Prognostic significance in long-term follow-up. Int J Colorectal Dis 23: 595-600, 2008.